• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Biological factors of prognostic significance in locally advanced breast cancer.

作者信息

Robertson J F, Ellis I O, Pearson D, Elston C W, Nicholson R I, Blamey R W

机构信息

City Hospital, Nottingham, UK.

出版信息

Breast Cancer Res Treat. 1994;29(3):259-64. doi: 10.1007/BF00666479.

DOI:10.1007/BF00666479
PMID:8049459
Abstract

The biological features of tumour type, histological grade, vascular invasion, mitotic index, DNA index, and oestrogen receptor (ER) and progesterone receptor (PgR) status have been investigated as prognostic factors in primary operable breast cancer. We have studied these 7 factors in locally advanced primary breast cancer (LAPC): these patients have occult metastases at presentation. Of 60 consecutive patients presenting with locally advanced disease, 36 were treated initially with Tamoxifen and 24 by radiotherapy. Treatment failure was followed by cross-over to the other therapy. All patients were assessed for response in the primary tumour; external review of response was obtained. Survival was compared using the generalised Wilcoxon test. Response to therapy correlated significantly with histological grade (p = 0.02), ER (p = 0.02), PgR status (p = 0.02), mitotic index (p = 0.01), and tumour ploidy (p = 0.04). Survival from initial therapy correlated significantly with ER (p = 0.01) and PgR status (p = 0.04). Histological grade, mitotic index, tumour ploidy, and ER and PgR status of the primary tumour predict response and prognosis in patients with locally advanced (stage III) breast cancer.

摘要

相似文献

1
Biological factors of prognostic significance in locally advanced breast cancer.
Breast Cancer Res Treat. 1994;29(3):259-64. doi: 10.1007/BF00666479.
2
Steroid receptors and prognosis in operable (stage I and II) breast cancer.类固醇受体与可手术(Ⅰ期和Ⅱ期)乳腺癌的预后
Eur J Cancer Clin Oncol. 1983 Oct;19(10):1381-7. doi: 10.1016/0277-5379(93)90007-r.
3
Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.他莫昔芬治疗的雌激素受体阳性转移性乳腺癌患者中孕酮受体水平的预后意义:西南肿瘤协作组前瞻性研究结果
J Clin Oncol. 1992 Aug;10(8):1284-91. doi: 10.1200/JCO.1992.10.8.1284.
4
Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.尿激酶型纤溶酶原激活剂及其抑制剂PAI-1:复发乳腺癌患者对他莫昔芬治疗反应不佳的预测指标。
J Natl Cancer Inst. 1995 May 17;87(10):751-6. doi: 10.1093/jnci/87.10.751.
5
Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.拓扑异构酶IIα及其他预后因素对晚期乳腺癌表柔比星化疗的预测价值
Br J Cancer. 1998 Jun;77(12):2267-73. doi: 10.1038/bjc.1998.377.
6
In vivo effect induced by interferon beta on steroid receptor status, cell kinetics and DNA ploidy in operable breast cancer patients.β-干扰素对可手术乳腺癌患者类固醇受体状态、细胞动力学和DNA倍体的体内作用。
Anticancer Res. 1995 Mar-Apr;15(2):537-41.
7
Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.雌激素受体(ER)和孕激素受体(PgR),通过配体结合分析与ER、PgR和pS2相比较,采用免疫组织化学法预测转移性乳腺癌对他莫昔芬的反应:一项西南肿瘤学组研究。
Int J Cancer. 2000 Mar 20;89(2):111-7.
8
[Receptor (ER, PgR) levels as prognostic factors in the endocrine therapy of pre- and post-menopausal patients with stage III infiltrative ductal and lobular cancer of the breast].[受体(雌激素受体、孕激素受体)水平作为绝经前和绝经后III期浸润性乳腺导管癌和小叶癌患者内分泌治疗的预后因素]
Ginecol Obstet Mex. 1996 Mar;64:135-9.
9
Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.孕激素受体缺失可识别在新辅助化疗后未达到病理完全缓解的患者中生存较差的腔面型局部晚期乳腺癌。
Oncotarget. 2015 Jul 20;6(20):18174-82. doi: 10.18632/oncotarget.4225.
10
Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.与第一肿瘤特征、内分泌治疗和放疗相关的对侧乳腺癌的预后、分期和雌激素受体状态。
Eur J Cancer. 2015 Nov;51(16):2304-13. doi: 10.1016/j.ejca.2015.07.016. Epub 2015 Aug 1.

引用本文的文献

1
Salubrinal Exposes Anticancer Properties in Inflammatory Breast Cancer Cells by Manipulating the Endoplasmic Reticulum Stress Pathway.Salubrinal通过调控内质网应激途径展现出对炎性乳腺癌细胞的抗癌特性。
Front Oncol. 2021 May 20;11:654940. doi: 10.3389/fonc.2021.654940. eCollection 2021.
2
Prediction of outcome in locally advanced breast cancer by post-chemotherapy nodal status and baseline serum tumour markers.通过化疗后淋巴结状态和基线血清肿瘤标志物预测局部晚期乳腺癌的预后
Br J Cancer. 2002 Dec 2;87(12):1404-10. doi: 10.1038/sj.bjc.6600616.
3
Preoperative assessment of prognostic factors in breast cancer.

本文引用的文献

1
A prognostic index in primary breast cancer.原发性乳腺癌的预后指数
Br J Cancer. 1982 Mar;45(3):361-6. doi: 10.1038/bjc.1982.62.
2
Monoclonal antibodies to human estrogen receptor.抗人雌激素受体单克隆抗体。
Proc Natl Acad Sci U S A. 1980 Sep;77(9):5115-9. doi: 10.1073/pnas.77.9.5115.
3
The assessment of histological differentiation in breast cancer.乳腺癌组织学分化的评估。
乳腺癌预后因素的术前评估。
J Clin Pathol. 2001 Jan;54(1):20-4. doi: 10.1136/jcp.54.1.20.
4
Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants.乳腺癌转移的分子生物学。炎性乳腺癌:临床综合征与分子决定因素。
Breast Cancer Res. 2000;2(6):423-9. doi: 10.1186/bcr89. Epub 2000 Jul 11.
Aust N Z J Surg. 1984 Feb;54(1):11-5. doi: 10.1111/j.1445-2197.1984.tb06677.x.
4
Assessment of response to treatment in advanced breast cancer. British Breast Group.
Lancet. 1974 Jul 6;2(7871):38-9.
5
Survival patterns in hormone treated advanced breast cancer.
Br J Surg. 1986 Sep;73(9):752-5. doi: 10.1002/bjs.1800730925.
6
Confirmation of a prognostic index in primary breast cancer.原发性乳腺癌预后指数的验证。
Br J Cancer. 1987 Oct;56(4):489-92. doi: 10.1038/bjc.1987.230.
7
Evaluation of an enzyme immunoassay for estrogen receptors in human breast cancers.人乳腺癌雌激素受体酶免疫测定法的评估
Cancer Res. 1986 Aug;46(8 Suppl):4299s-4302s.
8
The early results from a randomised study of radiotherapy versus Nolvadex (tamoxifen) as initial treatment for stage III breast cancer.
Eur J Surg Oncol. 1988 Jun;14(3):235-40.
9
The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast.接受内分泌治疗和化疗的晚期乳腺癌患者中“无变化”类别定义。
Eur J Cancer Clin Oncol. 1988 Oct;24(10):1567-72. doi: 10.1016/0277-5379(88)90046-6.
10
Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy.预测晚期乳腺癌患者对内分泌(甲地孕酮)治疗反应的因素。
Eur J Cancer Clin Oncol. 1989 Mar;25(3):469-75. doi: 10.1016/0277-5379(89)90259-9.